Colon Cancer Clinical Trial
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Summary
The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer
View Eligibility Criteria
Eligibility Criteria
Inclusion Criteria:
Measurable disease Tumor available for biopsies. Life expectancy of at least 3 months.
Exclusion Criteria:
Known or documented brain metastases prior to Cetuximab therapy.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
Submit
There is 1 Location for this study
See Locations Near You
Local Institution
Duarte California, , United States
Duarte California, , United States
Local Institution
Tampa Florida, , United States
Tampa Florida, , United States
Local Institution
Baltimore Maryland, , United States
Baltimore Maryland, , United States
Local Institution
St. Louis Missouri, , United States
St. Louis Missouri, , United States
Local Institution
New Brunswick New Jersey, , United States
New Brunswick New Jersey, , United States
Local Institution
Bronx New York, , United States
Bronx New York, , United States
Local Institution
Cincinnati Ohio, , United States
Cincinnati Ohio, , United States
Local Institution
Cleveland Ohio, , United States
Cleveland Ohio, , United States
Local Institution
Hershey Pennsylvania, , United States
Hershey Pennsylvania, , United States
Local Institution
Philadelphia Pennsylvania, , United States
Philadelphia Pennsylvania, , United States
Local Institution
Nashville Tennessee, , United States
Nashville Tennessee, , United States
Local Institution
San Antonio Texas, , United States
San Antonio Texas, , United States
Local Institution
Montreal Quebec, , Canada
Montreal Quebec, , Canada
Local Institution
Barcelona , , Spain
Barcelona , , Spain
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.